Accula™ SARS-CoV-2 Test
The Accula™ SARS-CoV-2 Test, which has received an Emergency Use Authorization (EUA) from the U.S Food and Drug Administration (FDA), is performed on the Accula™ Dock or the Silaris™ Dock and is a molecular in vitro diagnostic test utilizing polymerase chain reaction (PCR) and lateral flow technologies for the qualitative, visual detection of the coronavirus SARS-CoV-2 viral RNA. The Accula SARS-CoV-2 Test uses nasal swab specimens, collected from patients suspected of COVID-19 by their healthcare provider. Testing is authorized for laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high and moderate complexity tests. The Accula SARS-CoV-2 Test using nasal swab specimens is also authorized to be distributed and used in patient care settings outside of the clinical laboratory environment.
Specimen type: Nasal
Turnaround time: Approximately 30 minutes
CLIA Complexity: Moderate complexity/high complexity, authorized for use in patient care settings outside of the clinical laboratory environment
Ordering information:
Contact your Cardinal Health Laboratory Products Representative to order or complete the form below.
Material # | Description | Pkg string | Shipping UOM |
---|---|---|---|
COV4100 | Accula SARS-CoV-2 Test Kit |
25 test/kit | Drop ship only |
COV4100-1 | Accula SARS-CoV-2 Control Kit |
25 test/kit | Drop ship only |
Related information
Instructions for use
Fact sheet for patients
Fact sheet for healthcare providers
During this extraordinary time, Cardinal Health strives to provide customers with accurate product information but relies on the manufacturer for updates. Please visit the manufacturer's product website for the most current information.